ReviewThe Journal of clinical investigation2012
Multiple sclerosis.
Review in The Journal of clinical investigation, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02308137 (Open-label, Single-center, Single-arm Futility Trial Evaluating Oral Domperidone 10mg QID for Reducing Progression of Disability in Patients With Secondary Progressive Multiple Sclerosis), which is not on this map. Cited by 271 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Open-label, Single-center, Single-arm Futility Trial Evaluating Oral Domperidone 10mg QID for Reducing Progression of Disability in Patients With Secondary Progressive Multiple Sclerosis (SPMS)
Who cites it
271 citing papers in PubMed, 5 syntheses or guidelines pooled it, 477 citations in OpenAlex.
- Efficacy and safety of laquinimod versus placebo in relapsing-remitting multiple sclerosis: a systematic review and meta-analysis of randomized controlled trials.The Journal of international medical research · 2025Pooled it
- Single-cell transcriptome landscape of circulating CD4Cell genomics · 2024Pooled it
- Changes in Gut Microbiota and Multiple Sclerosis: A Systematic Review.International journal of environmental research and public health · 2023Pooled it
- Charting the proteome landscape in major psychiatric disorders: From biomarkers to biological pathways towards drug discovery.European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology · 2022Pooled it
- Absence of antibodies against KIR4.1 in multiple sclerosis: A three-technique approach and systematic review.PloS one · 2017Pooled it
- Administration of CD4BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2021Trial
- Molecular mimicry between Anoctamin 2 and Epstein-Barr virus nuclear antigen 1 associates with multiple sclerosis risk.Proceedings of the National Academy of Sciences of the United States of America · 2019Trial
- Article
- Anti-human T lymphocyte porcine immunoglobulin attenuates experimental autoimmune encephalomyelitis by inhibiting T cell activation.Scientific reports · 2026Article
- Thyroid-stimulating hormone receptor mediates peripheral-central neuroimmune crosstalk in autoimmune thyroid diseases.BMC medicine · 2026Article
- Anti-Neuroinflammatory Cannabinoid Acids as a New Therapeutic Approach for Multiple Sclerosis.Molecules (Basel, Switzerland) · 2026Article
- Association of cytokine levels with treatment duration and patient family history in Egyptian multiple sclerosis patients.Scientific reports · 2026Article
- Relation of inflammatory and oxidative biomarkers associated with relapse in pregnant women diagnosed with multiple sclerosis.Revista da Associacao Medica Brasileira (1992) · 2026Article
- CHI3L1 and CXCL13 Levels of Serum and CSF in Treatment-Naïve Multiple Sclerosis: Associations with Disease Activity.Noro psikiyatri arsivi · 2026Article
- Marine Bioactive Components and Chronic Neuroinflammation: Focus on Neurodegenerative Disease.Marine drugs · 2025Review
- Timing and Predictive Value of Clinical Conditions Preceding Multiple Sclerosis in the UK Biobank.Annals of clinical and translational neurology · 2025Article
- Biological therapy in a patient with coexistence of multiple sclerosis and ankylosing spondylitis: a case based review.Rheumatology international · 2025Review
- Notch2-expressing CD4Cellular & molecular immunology · 2025Article
- Beneficial Effects of Omega-3 Fatty Acids on Obesity and Related Metabolic and Chronic Inflammatory Diseases.Nutrients · 2025Review
- Stratifying Multiple Sclerosis Susceptibility Risk: The Role of HLA-E*01 and Infectious Mononucleosis in a Population Cohort.European journal of neurology · 2025Article
211 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 2 countries.
Funding
Abstract
Multiple sclerosis (MS) is a multifocal demyelinating disease with progressive neurodegeneration caused by an autoimmune response to self-antigens in a genetically susceptible individual. While the formation and persistence of meningeal lymphoid follicles suggest persistence of antigens to drive the continuing inflammatory and humoral response, the identity of an antigen or infectious agent leading to the oligoclonal expansion of B and T cells is unknown. In this review we examine new paradigms for understanding the immunopathology of MS, present recent data defining the common genetic variants underlying disease susceptibility, and explore how improved understanding of immune pathway disruption can inform MS prognosis and treatment decisions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.